Posted by Michael Wonder on 15 Jul 2026
Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
16 July 2026 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.
This follows the positive opinion issued by the EMA's CHMP in May 2026.
